The use of complementary and alternative medicine (CAM) in the general population and in patients with chronic diseases has increased markedly in recent decades. We aimed to determine the prevalence, type, and predictors of oral CAM use among patients with inflammatory bowel disease (IBD) compared with the general population in a large, population-based, case–control study.
Overall, 1370 patients with IBD and 598 control subjects in Canterbury, New Zealand, were recruited. Environmental and phenotypic data were obtained through a questionnaire and case note review. Predictors of oral CAM use were identified using binary logistic regression.
In the previous year, 44.1% of patients with IBD and 42.3% of control subjects used oral CAM (odds ratio [OR], 1.078; 95% confidence interval [CI], 0.885–1.312). The types of oral CAM used most frequently were vitamins (Crohn’s disease [CD], 25.2%; ulcerative colitis, 23.7%; control subjects, 24.9%), followed by herbs (CD 15.1%, ulcerative colitis 15.2%, control subjects 12.8%), and dietary supplements (CD, 8.5%; ulcerative colitis 12.6%, control subjects 12.1%). Female gender (OR, 1.61; 95% CI, 1.25–2.08), younger age (P = 0.005), higher education (P = 0.002), higher income (P = 0.04), being a vegetarian (OR, 3.58; 95% CI, 1.97–6.48) and a middle social class at birth (P = 0.024) were independent predictors of oral CAM use in patients with IBD. Disease phenotype was not associated with oral CAM use. In control subjects, female gender (OR, 2.67; 95% CI, 1.85–3.86), higher education (P = 0.003) and a diagnosis of asthma (P = 0.017) predicted oral CAM use.
Oral CAM use is common in, and does not differ between, patients with IBD and the general population in Canterbury, New Zealand. Socio-demographic factors, and not disease phenotype, predict oral CAM use in patients with IBD.
Article first published online 20 February 2013
Departments of *Gastroenterology and
†Clinical Pharmacology, Christchurch, Hospital, Christchurch, New Zealand
‡Department of Medicine, University of Otago, Christchurch, New Zealand
§Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand.
Reprints: Murray L. Barclay, MBChB, MD, Department of Gastroenterology, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand 8011 (e-mail: email@example.com).
The study was funded by the Canterbury Medical Research Foundation, Bowel and Liver Trust, Canterbury, Canterbury Gastroenterology Research Trust, and the New Zealand Society of Gastroenterology. M. Koning received a scholarship from Stichting dr. Hendrik Muller’s Vaderlandsch Fonds.
Received June 16, 2012
Accepted June 20, 2012